Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Py5.5
Pygeum – Forschung
Hilft wahrscheinlich
23 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Pygeum scheint in 3 von 3 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2000–2025 mit einer typischen Studiengröße von 455 Teilnehmenden.
Basierend auf 23 Studien · 2 Meta-Analysen · 1 RCT · 6,162 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
3geholfen· 20 weitere ohne bewertete Effektdaten
Nach Outcome
BPH & lower urinary tract symptoms
Hilft wahrscheinlich22 Studien
Men's vitalityReduzierte BPH-Symptome · 4-8 weeks
Überwiegend Mechanismus / Beobachtung9 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung5 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung5 Studien
In Zahlen
Aus 18 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
50%
über Studien hinweg
Untersuchte Personen
6,162
typische Studie: 455 Personen
Stärkste Designs
3
2 gepoolt, 1 randomisiert
Zeigte Nutzen
100%
3/3 Studien
Wie lange Studien liefen
3+ Monate
3
Untersuchte Populationen
Men with benign prostatic hyperplasia8
Men with BPH2
Breast cancer patients1
Various study populations1
Stetige Forschung
5 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2021
200020122025
1Urologic symptoms and flow measures in benign prostatic hyperplasiaMeta-Analysen=1,562 · large study2000
the evidence suggests that P. africanum modestly, but significantly, improves urologic symptoms and flow measures.
Ishani A et al. · The American journal of medicine (2000)
A total of 18 randomized controlled trials involving 1,562 men met the inclusion criteria and were analyzed.
Men were more than twice as likely to report an improvement in overall symptoms (risk ratio = 2.1, 95% CI: 1.40 to 3.1).
Nocturia was reduced by 19% and residual urine volume by 24%; peak urine flow was increased by 23%.
2LUTS symptom and flow rate improvementSystematische ÜbersichtCited 33×2008
P. africanum and H. rooperi showed an improvement in flow rates and symptoms compared to placebo, while S. cereale showed an improvement in symptoms but not flow rates compared to placebo.
Dedhia RC, McVary KT · The Journal of urology (2008)
We examined the available data from clinical trials for certain botanicals used for lower urinary tract symptoms secondary to benign prostatic hyperplasia, including Serenoa repens, Pygeum africanum, Secale cereale and Hypoxis rooperi.
P. africanum and H. rooperi showed an improvement in flow rates and symptoms compared to placebo.
Most clinical trials investigating the efficacy of botanicals suffer from well documented methodological flaws.
3Urological symptoms and flow measuresSystematische ÜbersichtCited 62×n=1,562 · large study2002
Compared to men receiving placebo, Pygeum africanum provided a moderately large improvement in the combined outcome of urologic symptoms and flow measures
Wilt T et al. · Cochrane Database of Systematic Reviews (2002)
A total of 18 randomized controlled trials involving 1562 men met inclusion criteria and were analyzed.
Men using Pygeum africanum were more than twice as likely to report an improvement in overall symptoms (RR=2.1, 95% CI = 1.4, 3.1).
Nocturia was reduced by 19%, residual urine volume by 24% and peak urine flow was increased by 23%.
4Breast cancer treatment outcomesSystematische ÜbersichtCited 5×2025
The findings suggested that East African medicinal plants hold promise as complementary treatments for breast cancer, offering potential benefits such as affordability, cultural appropriateness, and sustainability.
Alum EU et al. · Anti-cancer agents in medicinal chemistry (2025)
The findings suggested that East African medicinal plants hold promise as complementary treatments for breast cancer, offering potential benefits such as affordability, cultural appropriateness, and sustainability.
Further research into these plants and their bioactive compounds could revolutionize breast cancer treatment, improving survival rates and addressing the rising incidence of breast cancer-related fatalities.
Other: The review underscores the importance of continued research, conservation, and the integration of ancient healing methods to fully harness the potential of East African flora in breast cancer management.
5Biological activities of Prunus africanaSystematische ÜbersichtCited 10×n=455 · medium study2023
Many of the ethnobotanical assertions for the biological activity of P. africana have been confirmed through in vitro and in vivo studies.
Rubegeta E et al. · Journal of ethnopharmacology (2023)
Many of the ethnobotanical assertions for the biological activity of P. africana have been confirmed through in vitro and in vivo studies.
However, a disparity exists between the biological activity of the whole extract and that of single compounds isolated from the extract, which were reported to be less effective.
This finding suggests that a different approach to biological activity studies should be encouraged that takes all secondary metabolites present into consideration.
In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.
Csikós E et al. · Molecules (Basel, Switzerland) (2021)
DHT may promote prostate cell growth, resulting in hyperplasia.
Some medicinal plants and their compounds act by modulating this enzyme, and have the above-mentioned targets.
In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.
8Urinary symptoms in benign prostatic hyperplasiaSystematische ÜbersichtCited 55×2015
On the basis of preclinical studies several mechanisms of action have been postulated, including 5alpha-reductase inhibition, alpha-adrenergic antagonism, dihydrotestosterone and estrogen receptor ...
Allkanjari O et al. · Life sciences (2015)
On the basis of preclinical studies several mechanisms of action have been postulated, including 5alpha-reductase inhibition, alpha-adrenergic antagonism, dihydrotestosterone and estrogen receptor inhibition.
Randomized clinical trials indicate significant efficacy in improving urinary symptoms and mild adverse effects for some phytotherapeutic agents, while further clinical evidence is needed for others (e.g., Epilobium spp., Secale cereale, Roystonea regia).
Healthcare professionals should be constantly informed about BPH phytotherapy, taking into account the risk/benefit profile of the use of medicinal plants in the management of BPH.
9Lower urinary tract symptoms associated with BPHSystematische ÜbersichtCited 50×2014
This articles review the mode of action, the efficacy, and the safety, including herb-drug interactions of the most common botanicals (Serenoa repens, Pygeum africanum, Urtica dioica, and Cucurbita pepo) and nutraceuticals (isoflavones, lycopene, selenium, and β-Sitosterol) in controlling the lower urinary tract symptoms associated to BPH.
Pagano E et al. · Phytotherapy research : PTR (2014)
Histological BPH, which typically develops after the age of 40 years, ranges in prevalence from >50% at 60 years to as high as 90% by 85 years of age.
Typical symptoms include increased frequency of urination, nocturia, urgency, hesitancy, and weak urine stream.
Conventional medicines used for the treatment of BPH include alpha blockers and 5-alpha reductase inhibitors.
10Androgen receptor antagonism and prostate cancer cell growth inhibitionSystematische ÜbersichtCited 37×2011
Recently, atraric acid and N-butylbenzene-sulfonamide were isolated from a selective dichlormethane extract of P. africanum as two novel AR antagonistic compounds.
Roell D et al. · Molecular and cellular endocrinology (2011)
Recently, atraric acid and N-butylbenzene-sulfonamide were isolated from a selective dichlormethane extract of P. africanum as two novel AR antagonistic compounds.
The molecular mechanisms of AR inhibition were analyzed and are summarized here.
Both compounds are the first known natural, complete and specific AR antagonist.
Twenty years ago, the urologic community was encouraged by trial results that suggested phytotherapy could effectively treat symptomatic benign prostatic hyperplasia.
Keehn A et al. · Current urology reports (2016)
Twenty years ago, the urologic community was encouraged by trial results that suggested phytotherapy could effectively treat symptomatic benign prostatic hyperplasia.
Since that time, several well-constructed studies have consistently demonstrated that these agents are no more efficacious than placebo, despite being largely safe for ingestion.
Based on the available literature, there is no evidence that phytotherapy significantly improves symptoms of BPH against placebo, despite being largely safe for ingestion.
Keehn A et al. · The Canadian journal of urology (2015)
Based on the available literature, there is no evidence that phytotherapy significantly improves symptoms of BPH against placebo, despite being largely safe for ingestion.
In patients with mild BPH symptoms who are reluctant to take standard pharmaceutical medications may try these agents provided that the patient understands their current limitations.
Those with moderate or severe BPH should be discouraged from alternative and complementary treatments.
15Systematische ÜbersichtCited 5×2013
The scientific evidence on the use of phytotherapy in prostatic pathology is conclusive not recommend ing the use of it for BPH or the ADCP.
Morán E et al. · Actas urologicas espanolas (2013)
The scientific evidence on the use of phytotherapy in prostatic pathology is conclusive not recommend ing the use of it for BPH or the ADCP.
However, β-sitosterol, Pygeum africannum and Cernilton were reviewed in one study each, and significant improvement was observed for all three.
Kim TH et al. · Maturitas (2012)
However, β-sitosterol, Pygeum africannum and Cernilton were reviewed in one study each, and significant improvement was observed for all three.
All the included compounds have mild and infrequent adverse effects.
SRs on β-sitosterol, Pygeum africannum and Cernilton have not been updated since 2000, thus an update of reviews on these compounds will be necessary in the future.
These results, corroborated in part by short-term clinical efficacy, set the stage for a large-scale clinical trial to investigate the efficacy of Pygeum africanum extract in the treatment of lower urinary tract symptoms.Copyright (c) 2007 Wiley-Liss, Inc.
Edgar AD et al. · Neurourology and urodynamics (2007)
Furthermore, demonstration of their clinical efficacy in BPH has been hindered by trials of limited duration with a high placebo response.
Beginning with a preliminary demonstration of in vitro inhibition of growth factor-mediated fibroblast proliferation with Pygeum africanum extract, a detailed series of in vitro and in vivo studies on prostate growth and bladder function were undertaken.
These results, corroborated in part by short-term clinical efficacy, set the stage for a large-scale clinical trial to investigate the efficacy of Pygeum africanum extract in the treatment of lower urinary tract symptoms.
20IPSS total score reductionRCTCited 25×n=32 · small study2013
The herbal preparation (ProstateEZE Max) was shown to be well tolerated and have a significant positive effect on physical symptoms of BPH when taken over 3 months, a clinically significant outcome in otherwise healthy men.
Coulson S et al. · Complementary therapies in medicine (2013)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Borderline
There was a significant reduction in IPSS total median score in the active group of 36% as compared to 8% for the placebo group, during the 3-months intervention (p < 0.05).
The day-time urinary frequency in the active group also showed a significant reduction over the 3-months intervention (7.0-5.9 times per day, a reduction of 15.6% compared to no significant reduction change for the placebo group (6.2-6.3 times per day) (p < 0.03).
The night-time urinary frequency was also significantly reduced in the active group (2.9-1.8, 39.3% compared to placebo (2.8-2.6 times, 7%) (p < 0.004).